Daiichi Sankyo Healthcare Acquires All Shares of Im Co., Ltd.

Tokyo, Japan (October 2, 2015) – Daiichi Sankyo Company, Limited today announced that its subsidiary, Daiichi Sankyo Healthcare Co., Ltd. (hereafter, Daiichi Sankyo Healthcare), concluded an agreement on October 1 with MCP3 Limited Partnership Investment Business (hereafter, MCP3) to acquire all shares of Im Co., Ltd. (hereafter, Im), which was owned by MCP3.

1. Objective

Daiichi Sankyo Healthcare, which is responsible for a healthcare business comprising mainly of over-the-counter products, is aiming to make use of its product development capability as a drug manufacturer to strengthen its presence in fields such as skin care and oral care.

On the other hand, in addition to its marketing knowhow in mail-order business focused on skin care, Im has established a distribution base and support system for customers, including a call center, and is building a strong reputation for its flagship brand, Rice Force.

Through acquiring the shares of Im, Daiichi Sankyo Healthcare is aiming to rapidly build up the foundation for a mail-order business while further strengthening its presence in the skin care field.

2. Schedule

October 1, 2015: Conclusion of agreement regarding share acquisition
November 4, 2015: Transfer of shares (planned)
3. Company overview

1) Name: Im Co., Ltd.
2) Representative: Noritaka Numata
3) Location: Takamatsu City, Kagawa Prefecture
4) Established: 2005
5) Capital: 100 million yen
6) Sales: 5,811 million yen (as of February 2015)
7) Business content: Mail-order business dealing in cosmetics, health foods, etc.
8) Employees: 105 (as of September 30, 2015)

4. Effect on Financial Results

There will be an announcement at a later date regarding the effect of this acquisition on the financial results of Daiichi Sankyo Company, Limited, for the period ending in March 2016.